Sign inJoin waitlistJoin the waitlist

Kieran Sahasrabudhe

Internal Medicine Residency · University of Wisconsin Hospitals and Clinics

Credentials: · · ·

History

Internal Medicine
University of Wisconsin Hospitals and Clinics
2024–Present
Hematology and Medical Oncology
2027–2030
University of Rochester School of Medicine and Dentistry
2012–2016

Research

AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances
Review · Genes · 2020 · 54 citations
Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead
Review · Journal of Hematology & Oncology · 2024 · Co-senior of 3 authors · 34 citations
Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
Review · Blood and lymphatic cancer · 2020 · Co-first of 3 authors · 24 citations

Alice Mims
8 papers
Audrey Sigmund
2 papers · 2 as a fellow
Bhavana Bhatnagar
2 papers
CF
Charles Foucar
2 papers
Christine McMahon
2 papers
Jesus Lugo
2 papers
Joshua Zeidner
2 papers
Kristin Koenig
2 papers · 1 as a fellow
Michael Hochman
2 papers
OC
Onyee Chan
2 papers
RS
Ronan Swords
2 papers
Shivani Handa
2 papers

Clinical trials

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Site PI · Recruiting · Phase 1
Uma Borate
2024–2027